Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Botulinum Neurotoxin Assay Contract to Fluoresentric

by Global Biodefense Staff
June 12, 2013

The Centers for Disease Control and Prevention has announced intentions to solicit and enter into a sole source contract with Fluoresentric, Inc. for botulinum toxin assays.

The CbotA (16,000Rxn) and Cbot A (50,000 Rxn) real-time PCR singleplex assays developed by the Fluoresentric, Inc. are noted to be the only assays that can be utilized with existing, validated platforms for detection of botulinum toxin genes. 

“The PCR assays are required for support of federal, state, and local public health laboratories to detect Clostridium botulinum using existing protocols and platforms,” states the announcement. “In order to ensure that the assays perform as required, the assays must contain the identical oligonucleotide sequence and have the same specificity and sensitivity as that developed by Fluoresentric.”

Fluoresentric, Inc. is based in Park City, Utah.

The contract is on behalf of the CDC National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne and Environmental Diseases (DFWED), Enteric Diseases Laboratory Branch (EDLB).

Editor’s Note: While the small-scale procurement of laboratory equipment or reagents is commonplace, we periodically cover these activities for insight into the research, acquisition and mission priorities of biodefense-relevant organizations.

Tags: Botulinum Neurotoxin

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC